Adjuvanted vaccines afford invaluable protection against disease, and the molecular and cellular changes they induce offer direct insight into human immunobiology. Here we show that within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex molecular and cellular responses that included overt lymphoid as well as myeloid contributions. Unexpectedly, this early response was subtly but significantly different in people older than ~35 years. Wide-ranging adverse clinical events can seriously confound vaccine adoption, but whether there are immunological correlates of these is unknown.
The profound impact of immunization on public health is well illustrated by the reported efficacy of an Ebola-specific vaccine 1, 2 . Moreover, the potential applications of vaccines have broadened greatly as the biological implications of immunology have extended from infectious diseases, allergy and autoimmunity to metabolic disease 3 , neurodegeneration 4 and cancer 5 . Yet because most immunological experiments are undertaken in mechanistically tractable model systems, the understanding of human immune response dynamics has lagged behind.
This situation has been somewhat redressed by 'systems vaccinology' , faciliated advances in high-throughput analytical technologies and in informatics and biostatistics 6 . Thus, several studies have shown that many immunological metrics show little day-to-day variation 7, 8 , thereby permitting reliable measurements of responses to scheduled perturbations such as vaccination 6 , immune checkpoint blockade 9 or iatrogenic immune suppression 10 . Nonetheless, more studies are required to help establish general principles-for example, whether there are consensus immune signatures predicting poor responsiveness to particular modalities and whether discrete immunological phenotypes might be linked to adverse events (AEs). Transient AEs (sometimes dismissed as 'man flu') can undermine herd immunity by provoking diminished vaccination compliance and even halting vaccine trials 11 . Additionally, there have been highly public concerns that vaccines may exacerbate preexisting pathologies.
Influenza virus causes serious, potentially life-threatening disease. Because of seasonal strain variation, annual vaccination is recommended 12 . However, owing to year-to-year similarity among seasonal flu strains, vaccine responses commonly reflect flu-specific memory cell reactivation 8, 13 . Conversely, the human immune response dynamics (HIRD) study described here monitored the response to H1N1 'swine flu' that circulated in 2009 and was the first major H1N1 outbreak in several decades 14 . Whereas people older than 40 years might harbor swine flu-specific memory cells, this was unlikely in younger individuals who comprised the bulk of the HIRD cohort. Thus, the study offered an opportunity to investigate responses to flu vaccination that were not obviously dominated by recall responses.
Importantly, and in contrast to flu vaccines used in US immunemonitoring studies 8, 13, [15] [16] [17] , the UK H1N1 Pandemrix vaccine used here includes an adjuvant, AS03, designed to enhance immunogenicity 18, 19 . However, whether the early response differs quantitatively or qualitatively from nonadjuvanted flu vaccines has not hitherto been investigated by systems vaccinology. Interestingly, rather than being the sole province of myeloid cells, early phases of immune responses are increasingly acknowledged to include contributions from innate lymphoid cells and innate-like T cells, including γδ T cell crosspriming of CD8 + T cells [20] [21] [22] . Whether adjuvanted vaccines might promote such lymphoid stress surveillance is unknown.
The HIRD trial longitudinally tracked 178 healthy volunteers through two prevaccination and four post-vaccination time points. The trial's outcomes confirmed the practicality of high-throughput immune monitoring, which will be important as immunotherapies are more widely adopted. They established that within 24 h of receiving adjuvanted flu vaccine, healthy humans mount large and complex immune responses that include overt lymphoid contributions. This early response was slightly but substantially different in individuals aged more than ~35 years. In contrast to some reports 8, 13, [15] [16] [17] , vaccine nonresponsiveness seemed to reflect broad human phenotypic variation rather than any consensus prevaccination immune signature. Conversely, post-vaccination AEs reported by ~20% of the study volunteers were associated with a discrete molecular signature that was in turn frequently associated with an atypical, prevaccination B cell phenotype. Thus, individual variation in immune composition can have complex pathophysiological manifestations. This notwithstanding, vaccination did not obviously exacerbate existing immune dysregulation.
RESULTS

Expansive transient responses to adjuvanted vaccination
From March 2010 to August 2011, the HIRD study enrolled 178 healthy adult volunteers (aged 18-65 years) with no known history of cancer, immunodeficiency, autoimmune or inflammatory diseases and no recent infection or vaccine exposure ( Table 1 and Supplementary Table 1 ).
Volunteers underwent a standard health examination, including blood and urine analysis, after which they completed six morning visits on prevaccination days −7 and 0 and post-vaccination days 1, 7, 14 and 63 ( Supplementary Fig. 1) . At each visit, fasting peripheral blood was sampled and banked. At the end of the day 0 visit, volunteers received a single intramuscular injection of the swine flu vaccine Pandemrix, which comprised 3.75 mg antigen from the A/California/7/2009 H1N1 virus strain in adjuvant AS03, which contains dl-α-tocopherol (vitamin E), squalene and polysorbate 80. At day 63, serological vaccine responses were measured at the UK Health Protection Agency (HPA) by both hemagglutination inhibition (HAI) and microneutralization (MN). Responders were defined, by convention, as those showing ≥4-fold increases in titer in one or both assays. Approximately 20% of volunteers were nonresponders ( Table 1) . At all visits, volunteers completed Likert wellness assessments 23 , which showed that ~20% of males and ~25% of females experienced above-average clinical AEs, primarily at day 1 ( Table 1) . We assessed sera from 139 of the 178 volunteers by multiparameter Luminex and analyzed the white blood cells of 60 people from this subset by flow cytometry; from this group 46 individuals had their peripheral blood gene expression on days -7, 0, 1 and 7 assessed by microarray, (Supplementary Fig. 1a ). Thus, all subjects whose gene expression was assessed were also assessed by all other methods. All platforms were subject to rigorous quality controls (Online Methods).
Of the volunteers analyzed, essentially all showed expansive changes in peripheral blood gene expression by day 1 (significant changes in ~9,000 gene probes (P < 0.05)) ( Supplementary Fig. 2a ), highly consistent with other studies that did not use adjuvants 8, 16, 24, 25 . Quantitative reverse transcription PCR of 30 randomly selected genes across ~20 individuals provided independent validation of the microarray quantification at each time point ( Supplementary Fig. 2b,c) . Collective gene-expression patterns on day 1 differed significantly from those at prevaccination time points (days −7 and 0) as well as those on day 7 (Fig. 1a) . Predictably, many of the genes most highly upregulated at day 1 encode and/or are associated with antigen presentation and interferon responses ( Fig. 1b) . Largely explaining this, most individuals at day 1 showed transient but significant (1.6-fold, on average) increases in the blood monocyte fraction and slight but significant decreases in numbers of recoverable peripheral blood cells ( Fig. 1c and Supplementary Fig. 2d ). Of note, for the 46 individuals assessed by microarray, the increases in monocyte numbers were significantly smaller than the changes (up to 160-fold) in expression of more than 135 genes, including those encoding activationsensitive regulators (for example, STAT1 (>16-fold) and IRF1 (6-fold), IRF7 (>3.5-fold), IRF9 (>2.5-fold)), and markers of cell activation (for example, multiple genes encoding class II human leukocyte antigens (HLA-DR) (2-to 2.5-fold) and TLR8 3.5-fold) ( Supplementary  Fig. 2e ). Thus, vaccination rapidly induced changes in peripheral blood mononuclear cell (PBMC) gene expression over and above the changes induced in PBMC composition. Most day 1 changes returned to baseline by day 7, by which time blood plasma cell counts were greatly increased, as was the expression of >1,000 genes, many associated with plasma cells (Fig. 1a,b,d and Supplementary Fig. 2a) .
Changes in peripheral blood monocyte composition and gene expression at day 1 were associated with increased blood concentrations of cytokines and chemokines, notably CCL4, CCL2, interleukin 6 (IL-6) and granulocyte-colony stimulating factor (G-CSF), mostly attributable to myeloid cells 7, 13, 26 (Fig. 1e) . Unexpectedly, however, the biggest fold-change was in interferon-γ (IFN-γ), a cytokine associated with type 1 helper T cells (T H 1 cells), cytolytic T cells, γδ T cells, natural killer T (NKT) cells, NK cells and type 1 innate lymphoid cells ( Fig. 1e) . Thus, the expansive, multifaceted transient changes in blood cell composition and gene expression that occurred within 24 h of receiving adjuvanted H1N1 vaccine included a distinct lymphoid contribution. 
Early myeloid and lymphoid activation
The changes in day 1 peripheral blood monocyte composition and gene expression ( Supplementary Fig. 3a ) were reflected in monocyte activation, as evidenced by significant increases in the percentage of cells expressing HLA-DR and in the amount per cell of surface-expressed HLA-DR ( Fig. 2a,b ). By contrast, we observed significant, transient decreases in T cell representation and in transcripts encoding T cell functions, particularly signaling molecules (for example, CD247, ZAP70, LCK, LAT and FYN) ( Supplementary Fig. 3a and Fig. 2c ). These findings do not simply counter-balance the increases in blood monocytes, because the losses among CD8 + αβ T cells and γδ T cells were mostly confined to HLA-DR − CD38 − cells. Thus, the blood became de facto enriched in activated lymphocytes, particularly HLA-DR + CD38 + cells ( Fig. 2d) .
A functional consequence of early myeloid and lymphoid activation was the overt upregulation of myriad interferon-stimulated gene transcripts (ISGs) ( Fig. 2e) . Although many ISGs probably reflected the actions of type I and III interferons (IFN-α and IFN-λ), they also included CXCL9 ( Fig. 2e and Supplementary Fig. 2c ) which is much more strongly upregulated by IFN-γ. Moreover, the day 1 peak in blood protein concentration of CXCL10, which can be upregulated by IFN-α or IFN-γ, paralleled IFN-γ expression ( Fig. 2f ) rather than IFN-α expression, which peaked at day 7. Notably, the increases in IFN-γ and IFN-α serum protein concentrations were not mirrored in the transcripts of their encoding genes IFNG and IFNA4 (or IFNλ-encoding genes IFNL1 and IFNL2) on day 1 or day 7 ( Fig. 2e) . This paradox might reflect enhanced interferon protein synthesis and/or secretion rather than increased gene expression. Additionally, peripheral blood ISGs may have been upregulated by interferon proteins leaking into the blood from interferon-expressing cells within the vaccine injection site and/or the associated lymph nodes.
Among serum cytokines and chemokines, the most notable early marker of immune challenge was CXCL10, in part because baseline concentrations were consistently low: whereas >90% of 130 subjects had prevaccination CXCL10 concentrations <1 ng/ml, this was the median concentration by day 1 (Fig. 2f) . Although significant (P < 0.05, two-tailed paired t-test) increases also occurred in tumor necrosis factor (TNF) and IL-6, the prevaccination concentrations of these cytokines showed high individual variation, which increased after vaccination ( Supplementary Fig. 3b ). Likewise, inter-individual variation largely obscured dynamic responses of other myeloid and lymphoid mediators, with post-vaccination expression of some molecules (such as IL-10) best described by a bimodal distribution ( Supplementary Fig. 3c ). This notwithstanding, significant (P < 0.05, two-tailed paired t-test) day 1 increases were evident for CCL5, another lymphoid cytokine ( Supplementary Fig. 3d ). In sum, adjuvanted H1N1 vaccine rapidly upregulated multiple myeloid and lymphoid effector functions, including type I and type II interferons.
Age affects early responses
This study was not designed to explore the well-established compromise in adaptive responses in subjects older than 70 (refs. 27,28) . However, we unexpectedly identified subtle but significant impacts npg r e s o u r c e of age on day 1 gene expression. Forty subjects for whom geneexpression data were available across two prevaccination and two postvaccination time points were grouped into successive younger and older subsets by a barrier method-that is, the youngest five were compared to the remaining 35 (i5); the youngest 6 to the remaining 34 (i6) and so on, through to the youngest 35 being compared to the remaining five (i35) ( Supplementary Fig. 4 and Fig. 3a ). This revealed a pattern not seen when subjects were randomly partitioned into 10 5 different, comparably sized groupings. Specifically, the aggregate day 1 gene-expression signature was significantly different when ranks above i19 (Fig. 3b) were compared with younger subjects. At this point of divergence in gene expression, the median ages of the comparison groups were >40 and ~22, respectively ( Fig. 3a) . Moreover, at i21, where divergence was very significant, the minimum age of the older group was ~30 (Fig. 3a) . This indicated that significant changes in the early response profile may occur at 30-40 years z-score npg r e s o u r c e of age, much younger than is usually considered in the context of age-related immune dysregulation. Notably, transcripts underpinning the age-dependent differences included several that are functionally implicated in the early response (such as TBX21, CD38 and CD28), and others implicated in immune regulation (such as HDAC4) (Supplementary Table 2 ).
Building on these findings we divided subjects into groups by age (above or below 35 years). The day 1 increases in IFN-γ and CXCL10 serum concentrations, and the peripheral blood lymphocyte (PBL) depletion of CXCR3 + CD8 + T cells were all significantly lower in the older cohort (P < 0.05, IFN-γ and CXCL10 two-tailed Mann-Whitney test; CXCR, CD8 T cells two-tailed paired t-test) ( Supplementary Fig. 5a,b) . Although the most profound impact of age on gene expression was at day 1, there were also some significant differences in prevaccination lymphocyte subset counts in the older group (Supplementary Fig. 5c ). Perhaps consistent with this, six age groupings (i27-i32) showed significant divergence in prevaccination gene expression ( Fig. 3b) .
It might be hypothesized that the difference in day 1 responses is a reflection of younger subjects' making primary responses versus older subjects' making efficacious recall responses. However, the changes in titer (0-to >10 2 -fold) of influenza-specific antibodies, measured by HAI or MN, were spread similarly across subjects with low and high prevaccination titers and showed no correlation with age ( Supplementary Fig. 5d ). Consistent with this, the day 7 plasmablastdominated gene-expression pattern was mostly unaffected by age ( Fig. 3b) , with only one group (i30) showing a substantial divergence, possibly reflecting its inclusion (relative to i31) of a profound nonresponder aged 48 years. In sum, the available data did not obviously support the idea that the early response in those aged more than ~35 years is altered by a shift toward making recall responses.
When we did an analogous assessment of subjects grouped by sex, the peripheral blood gene-expression patterns at all time points showed sexual dimorphism, as reported 29 (Supplementary Fig. 5e ). However, this dimorphism was removed after normalization of gene expression at each time point to expression at day −7 prevaccination. Thus, the capacity of vaccination to induce expansive changes in gene expression was essentially unaffected by preexisting differences in the gene-expression profiles of males and females.
Broad phenotypic variation underpins vaccine nonresponse
Compliant with international guidelines, subjects showing ≥4-fold increases in influenza-specific antibodies measured by HAI and MN were defined as responders. Approximately 80% were responders ( Table 1 and Fig. 4a) , whereas ~70% were reported as such in Pandemrix efficacy trials 18 , probably reflecting HIRD's stringent exclusion criteria. We observed a complete spectrum of preexisting HAI and MN titers (Fig. 4a) among nonresponders, including 'baseline' nonresponders, whose low starting titers did not increase ≥4-fold, and 'glass ceiling' subjects, whose high starting titers made enhancements by ≥4-fold harder to achieve.
The frequency distribution of the day 63/day 7 MN titer ratios adhered to an additive model of two quasi-Gaussian distributions that respectively partitioned the HIRD cohort into one group with a very broad range of ratios between 0 and >30 and one with a narrow range of MN ratios, mostly ≤5 (Fig. 4b) . This model suggests that nonresponders may have arisen from at least two groups of subjects, challenging the prospect of a consensus origin of vaccine failure. To further investigate this, we compared gene-expression patterns of 23 responders and 18 nonresponders. The most common nonresponse pattern was reduced expression of genes associated with plasma cell development and antibody production ( Fig. 4c) , as reported 8, 17, 24, 30, 31 , coupled with a poor (albeit not absent) day 7 expansion of CD27 + CD38 hi plasmablasts (Fig. 4d) . Conversely, B cell genes highly expressed by responders included three that were linked to responsiveness in other studies (MZB1, TNFRSF17 and XBP1) 8, 17, 24, 31 (Supplementary Fig. 6a) .
Although nonresponders shared a failure to activate plasmablasts, there were many different 'routes to failure' as illustrated when we tracked the day −7, 0 (prevaccination), 1 and 7 gene-expression patterns, represented by principal components, for six baseline nonresponders relative to the consensus responder pattern (Fig. 4e) . Thus, subject 402B did not significantly alter any genes; subject 39 altered many day 1 genes but returned to baseline; subject 3 started with an atypical pattern and regulated day 1 genes but did not progress beyond that; subject 11 regulated some genes on day 7 but without a preceding day 1 signature; subject 12 regulated day 1 genes but did not reach the day 7 signature; and subject 164 started with a highly atypical pattern and reverted toward the consensus prevaccination signature. Thus, nonresponders presented a broad spectrum of phenotypes.
Consistent with this, no common nonresponder signature could be found among individual and combinatorial cell phenotyping and analyte-expression patterns. There was a significant association with higher frequencies of activated γδ T and NK cells at all time points ( Supplementary Fig. 6b-d) , but these frequencies were so variable among individuals that high frequencies could not predict nonresponsiveness. Baseline nonresponders often showed higher IL-17 concentrations than responders and glass-ceiling nonresponders, but, again, IL-17 concentrations could not effectively segregate the groups (Supplementary Fig. 4d ). In sum, neither molecular nor cellular data offered any consensus prevaccination predictor of nonresponsiveness akin to those proposed in studies of nonadjuvanted vaccines 8 a b Figure 3 Age factor in multivariate analysis of gene expression based on all genes. (a) Age statistics for groups separated by barrier method ( Supplementary Fig. 4 ) defining the maximum, median and minimum age of subjects assigned as 'young' and 'old' for each value of i in our subject cohort. (b) Increasing subject age rank plotted against permutation test P values for a multivariate statistic t (m.v.t.), which quantifies Pearson dissimilarity between age groups, representing all possible partitions of subjects into 2 age groups of at least 5 subjects. P values are estimated with respect to 10 5 random reassignments of age to subject. Vertical red line (a,b) indicates inflection point at which age factor becomes a significant influence (m.v.t. permutation P < 0.05) on gene expression in the day 1 data set.
r e s o u r c e
Peripheral blood signature of pathophysiology Using well-established methods for quantifying patients' perception of symptoms such as pain 23 , we assessed short-term clinical outcomes of all subjects across a spectrum of AEs (Fig. 5a) . Most AEs were related to day 1, with fewer prolonged events captured from day 1 to day 7.
After pooling these two time points, we grouped subjects by high, medium and low AE. There was no obvious correlation between AEs and gender, age or vaccine responsiveness (Table 1 and Fig. 5b) .
Given that the HIRD cohort was healthy with no known immunological dysregulation, we initially considered that high and medium npg r e s o u r c e (high/medium) AEs might reflect exaggerated, innate-like recall responses of memory lymphocytes. However, neither prevaccination memory T cell numbers (Supplementary Fig. 7a,b) nor baseline antibody titers were correlated with AEs. Although subjects with high/medium AEs collectively showed higher day 1 CXCL10 upregulation, inter-individual variation confounded the possibility of using npg r e s o u r c e CXCL10 concentrations to distinguish those with high/medium AEs (Fig. 5c) . Moreover, AEs did not correlate with circulating TNF, IL-6 or IFN-γ concentrations or with commonly employed markers of inflammation, including serum amyloid A and C-reactive protein ( Fig. 5c,d) . By contrast, those with high/medium AEs showed notably higher transient day 1 expression of a small set of genes, including LNX2, BCL2L14, RARRES3, KRT9, CNDP2, RM12 (MRPL12), METTL6 and TGM2 (Fig. 5e) . Although it remains to be seen whether any such genes directly relate to clinical symptoms, their capacity to segregate the HIRD cohort into those with high/medium AEs asserts a bona fide peripheral blood signature of self-reported vaccination-associated illness.
Transitional B cells, autoimmunity and AEs
To investigate whether any prevaccination immunological profile might identify people prone to AEs, we further investigated differential gene expression. We found, unexpectedly, that the PBMCs of subjects with high/medium AEs overexpressed many B cell genes (relative to subjects with low AEs), before and after vaccination ( Fig. 6a and Supplementary Fig. 8a) . This signature often correlated with a prevaccination over-representation of CD27 − CD38 hi CD24 hi transitional B cells (Fig. 6b) , a trend that gained statistical significance immediately after vaccination (Fig. 6c) . By contrast, AEs showed no association with total B cell counts (Fig. 6d) . Prevaccination transitional B cell numbers have been linked with nonresponsiveness after adjuvant-free flu vaccination 8 . However, our study found no correlation between vaccine efficacy and the percentages of transitional B cells, memory B cells or naïve B cells (Supplementary Fig. 8b,c) , whether responsiveness was classified as a categorical variable (≥4-fold increases in titer) or as a continuous variable. Indeed, baseline nonresponders were spread across the full spectrum of transitional B cell subset representation (Supplementary Fig. 8b) .
Interestingly, transitional B cell expansion has been associated with autoimmunity 32, 33 . Therefore, to further test the unanticipated association of transitional B cells with pathophysiology, we investigated whether subjects with high/medium AEs might harbor autoantibodies despite being outwardly healthy. We found that 8 of 31 subjects with high/medium AEs, in contrast to only 1 of 37 subjects with low AEs, showed high-titer prevaccination reactivities to thyroglobulin and/or thyroid peroxidase, two specificities commonly tested for in the clinic (Fig. 6e) . Of note, however, vaccination did not affect autoantibody titers, as assessed from day −7 to day 63 (Fig. 6f) . In sum, there was within the healthy HIRD cohort a subpopulation with increased frequencies of transitional B cells, one-quarter of whom unknowingly harbored autoantibodies of potential clinical significance, and this subpopulation was more prone to developing AEs in response to adjuvanted H1N1 vaccine.
DISCUSSION
Vaccines remain a cardinal plank of public health, and several strategies are used to promote their immunogenicity. For example, an Ebola npg r e s o u r c e vaccine reported in 2015 used vaccinia virus to deliver DNA encoding an Ebola antigen 2 . An alternative strategy delivers antigens in the context of adjuvants, such as AS03 in the Pandemrix H1N1 vaccine. AS03 markedly enhances B cell responses to bird flu when compared to another adjuvant, MF59, or to no adjuvant 34 . However, the human immune response to adjuvanted flu vaccines has not been assessed by systems vaccinology.
In that regard, our study shows that the Pandemrix H1N1 vaccine provokes rapid and expansive, yet transient, activation of myeloid cells and effectors, similarly to changes induced by other vaccines, including flu vaccines lacking adjuvant 8, 13, [15] [16] [17] . However, our study also reveals a pronounced lymphoid contribution to the early phase of the immune response, most evident in the prominent transient upregulation of IFN-γ, which was not apparent in most other virus vaccine studies. IFN-γ increases apparent at day 2 after administration of yellow fever vaccine 35 were not statistically significant. Conversely, IFN-γ RNA was upregulated in muscles of mice 4 h after injection of AS03 and viral antigens, with IFN-γ detected in the draining lymph nodes 19 . The functional consequences of IFN-γ upregulation remain to be clarified but may, at minimum, include CXCL9 and/or CXCL10 upregulation, as their expression closely paralleled that of IFN-γ in our study and in AS03-treated mice.
The issues remaining to be clarified include (i) the degree to which rapidly induced IFN-γ and/or other lymphoid effectors explain the efficacy of AS03 and other adjuvants, (ii) the cell types most responsible for the early lymphoid response and (iii) the molecular cues that promote the rapid activation of those cell types. For now, however, the data offer strong support for the idea that in some circumstances, lymphoid stress surveillance may be a key component to the early phase of the immune response. In that regard, the early enrichment for HLA-DR + CD38 + activated effector T cells in our study contrasted with delayed increases in those cells after smallpox or yellow fever vaccination 35, 36 .
Within the HIRD cohort, a prominent day 7 plasmablast signature correlated strongly with vaccine responsiveness, as was true for several flu and other viral vaccines. Nonetheless, the size of the HIRD study exposed the large scale of human immunophenotypic variation and, therein, the many routes by which plasmablast activation may fail. Thus, the HIRD study did not identify a consensus prevaccination predictor of nonresponsiveness. This was true even when the convention of using ≥4-fold increases to define responders was substituted with a continuous range and when markers and predictors of nonresponsiveness reported by others 8, 13, [15] [16] [17] were specifically investigated (although we did not perform a detailed examination of follicular helper T cells) 8, 37 . There was also no association of HLA haplotype with any criteria measured in the HIRD study.
The difficulty in identifying a consensus nonresponder signature seems consistent with a published twin study that suggests that phenotypic, experiential variation has a more profound effect on vaccine responses than genetics 38 . Wide-ranging immunophenotypic variation may likewise underlie current difficulties in identifying predictive signatures of nonresponsiveness in cancer immunotherapy. Conversely, the emergence in HIRD and other trials of markers, particularly CXCL10 (ref. 24) , that robustly reflect recent immunological challenge may form the basis of a consensus 'immune responsiveness signature' by which patient responses to a spectrum of interventions can be easily gauged in the clinic.
Age is a fundamental component of experiential variation, and marked declines in adaptive responsiveness in the elderly are well known and increasingly well understood 7, 27, 39, 40 . By contrast, age-related differences in the early (day 1) response, such as those described here, have not been widely considered. Moreover, those differences appeared to emerge at younger ages (~35 years) than are usually considered in the context of age-related immune dysregulation. Neither the basis nor consequences of those differences are yet known, but the findings emphasize how responses to vaccines, allergens and infections might be different for younger adults, with the potential to influence the design of efficacious vaccines and immune-therapeutics.
Whereas there may be many ways to fail to make an effective vaccine response, there may be only few routes to developing AEs of the broad spectrum assessed in this study. Vaccine-related AEs can pose serious obstacles to vaccine approval and to public compliance with vaccination regimens. Thus, concrete cellular and molecular patterns associated with symptoms of AEs may offer ways to limit such events and/or stratify patients. In this regard, our study provides evidence that high/medium AEs reported equally by men and women are associated with a discrete post-vaccination gene signature. Most unexpectedly, however, AEs were also associated with a prevaccination gene-expression pattern that was in turn commonly manifest in an atypical B cell phenotype. Moreover, this atypical phenotype predicted that several subjects reporting AEs harbored autoantibodies. More than one-quarter of the medium/high-AE cohort scored positive in tests of only two clinically relevant specificities. Thus, whereas it is well established that human immonophenotypic variation can affect immune responses to pathogens and/or provoke clinical autoimmunity, our study has established how such variation in healthy adults may also be associated with complex, subclinical pathophysiology whose consequences are manifest only on challenge and whose read-outs are not overtly immunological. Therefore, as algorithms and data-analysis tools grow in power, together with clinical phenotyping and molecular pathology, so practical monitoring of peripheral blood may identify discrete forms of human immunophenotypic variation that collectively predict a broad spectrum of pathophysiological conditions and/or responses to treatment.
METHODS
Methods and any associated references are available in the online version of the paper. groups. Namely, 10 5 realizations of the Fisher-Yates shuffle are used to estimate p = Pr(T ≥ t). An important advantage of such a permutation test is that it takes into account correlation between probes.
Analysis of potential effect on gene expression of subject age presented additional challenges and was conducted as follows. Because factor day has a strong effect on gene-expression patterns, effect of age is investigated at each day separately. To enable comparison of age effect at different days, the data set is reduced to the 40 subjects having gene-expression data for days 0, 1 and 7. Using m.v.t. to examine age effect requires defining age groups for permutation testing. An exhaustive approach to defining age groups consists in enumerating all possible partitions of subjects into 'young' (Y) and 'old' (O) groups of size at least 5 and reporting m.v.t. P values for each partition. Such enumeration is performed via a "barrier" approach: subjects are sorted by ascending age and the first r (Y) are compared to the remaining 40 − r (O). The profile of m.v.t. P values as a function of age rank r (5 ≤ r ≤ 35) provides an estimate of effect of subject age on gene expression. When subjects have the same age on both immediate sides of the barrier, all possible partitions are enumerated and the reported m.v.t. P value is the average over these partitions.
To find specific genes changing expression levels upon vaccination, we used all QC-approved samples and fitted (with R package limma) a linear model with time point as categorical variable, treating both time points before vaccination as repeated measures and subject as a blocking variable. Genes with expression levels different between any two time points (before vaccination, 1 d after, 7 d after) were identified by moderated t-test; cut-offs for q value and fold change were 0.05 and 1.5 or 2. For genes with several probes per gene, per-probe information was collapsed to per-gene information by arbitrary picking a probe with lower P value in first day after vaccination to prevaccination comparison in all individuals.
To find genes expressed differentially in vaccine responders and nonresponders, only individuals with samples available from both post-vaccination and a prevaccination time points were analyzed (39 individuals). Three different approaches were used. To detect genes expressed differently between Rs and NRs at separate time points, a linear model was fitted with limma, with responder status and time point as categorical variables and individual treated as a blocking variable. To detect genes with change in expression between time points different between Rs and NRs, prevaccination expression level was treated as a baseline and subtracted from later measurements; then genes changing differently were identified with limma-fitted linear model (time and responder status as categorical variables) and moderated t-test, or by fitting time course quadratic profiles with maSigPro (https://bioc.ism.ac.jp/packages/2.12/bioc/html/maSigPro.html). Unless otherwise mentioned, cut-offs for q value and fold change were 0.05 and 0.5.
Differences between individuals with and without AEs were identified in the same way as described for differences between responders and nonresponders, with low and medium/high AE defined as above.
Statistical analysis. Statistical analysis, significance cut-offs, and other analyses for the microarray data were performed following standard array analysis techniques. Flow cytometry, serum biochemistry, and serum analyte data were analyzed using Prism software. Data are reported as mean ± s.d. or median and interquartile range. Multiple samples were compared using one-way ANOVA where all data points for each sample were available, and using the Wilcoxon rank sum test, Student's t-test, or the Mann-Whitney nonparametric test, as appropriate to the analysis. Categorical data were compared by calculating the standard Normal deviate and two-tailed P value and are reported as mean (95% confidence interval). 
